IV administration has previously been shown to be safe in a phase 1 trial of VSV-IFNβ with a sodium iodide symporter (VSV-IFNβ-NIS) in relapsed hematological malignancies, so we sought to evaluate the safety of administering our therapy IV in addition to IT (16). This evidence concerns the gene SLC5A5 and hematologic disorder.